[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 80 of about 80
1. Uzquiano MC, Prieto VG, Nash JW, Ivan DS, Gong Y, Lazar AJ, Diwan AH: Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol; 2008 May;21(5):540-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma exhibits reduced actin expression.
  • Basal cell carcinoma is the most common malignancy in Caucasian individuals.
  • Metastatic basal cell carcinoma is extremely rare (with a rate estimated as 0.03%).
  • Actin has been detected in aggressive forms of basal cell carcinoma, but their expression in metastatic lesions is not known.
  • We compared the expression of actin and actin-related cytoskeletal proteins in relatively less aggressive basal cell carcinoma (nodular), aggressive basal cell carcinoma (infiltrative/morpheaform), and metastatic basal cell carcinoma.
  • We studied 12 cases of nodular basal cell carcinoma, 10 cases of infiltrative basal cell carcinoma, and 10 cases of metastatic basal cell carcinoma with immunohistochemistry for alpha-smooth muscle actin, calponin, myosin, and E-cadherin.
  • Five of the ten patients with metastatic basal cell carcinoma had an antecedent history of radiotherapy.
  • Actin was present in 3 of 12 (25%) of the nodular, all 10 of the infiltrative, and 3 of 10 of the metastatic basal cell carcinomas (P<0.05 for metastatic vs infiltrative and nodular vs infiltrative).
  • Calponin was present in 50% of the nodular, 60% of the infiltrative, and 30% of the metastatic basal cell carcinomas (not statistically significant).
  • E-cadherin was present in 75% of the nodular, 70% of the infiltrative, and all of the metastatic basal cell carcinomas (P<0.05 for metastatic vs nodular).
  • [MeSH-major] Actins / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223552.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Cadherins; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; EC 3.6.4.1 / Myosins
  •  go-up   go-down


2. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ: The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials; 2010 Apr 21;11:42
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma is the commonest human cancer.
  • To compare excisional surgery with imiquimod cream for nodular or superficial basal cell carcinoma in low risk sites, with respect to 3 year clinical clearance, cost-effectiveness and cosmetic results.
  • METHODS/DESIGN: Five hundred participants with low risk nodular or superficial basal cell carcinoma will be recruited from hospitals to this multi-centre, randomised, parallel group, controlled phase III trial.
  • Treatment in the imiquimod group is for 6 weeks for superficial basal cell carcinoma and 12 weeks for nodular basal cell carcinoma.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):840-5 [19438849.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Am J Epidemiol. 2004 Apr 1;159(7):702-6 [15033648.001]
  • [Cites] J Dermatol Surg Oncol. 1986 Aug;12(8):860-5 [3734238.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] Br J Dermatol. 1994 Dec;131(6):914-5 [7857854.001]
  • [Cites] Arch Dermatol. 1997 May;133(5):593-6 [9158412.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1177-83 [10522664.001]
  • [Cites] Arch Dermatol. 1999 Oct;135(10):1255-9 [10522675.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD003412 [17253489.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2105-8 [17640064.001]
  • [Cites] J Clin Epidemiol. 2009 May;62(5):464-75 [19348971.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • (PMID = 20409337.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN48755084; ClinicalTrials.gov/ NCT00066872
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; P1QW714R7M / imiquimod
  • [Other-IDs] NLM/ PMC2877028
  •  go-up   go-down


3. Lesiak A, Slowik-Rylska M, Rogowski-Tylman M, Sysa-Jedrzejowska A, Norval M, Narbutt J: Risk factors in Central Poland for the development of superficial and nodular basal cell carcinomas. Arch Med Sci; 2010 Apr 30;6(2):270-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors in Central Poland for the development of superficial and nodular basal cell carcinomas.
  • INTRODUCTION: In the last decades the number of skin carcinomas has dramatically increased, which is mainly connected with changes in lifestyle, especially with common use of artificial light sources such as sunbeds.
  • Basal cell carcinoma (BCC) is the most common form of skin cancer in white populations.
  • Basal cell carcinomas are divided into subtypes, depending on their clinical picture and histology.
  • The main groups are nodular (nBCC) and superficial (sBCC) ones.
  • The major recognized risk factors for basal cell carcinoma (BCC) are exposure to chronic and intermittent burning doses of sunlight.
  • RESULTS: No statistical differences were observed between the BCC subtype and sex, age, hair colour, eye colour, smoking, family history of skin cancer, occupation, or past episodes of sunburn.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22371758.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3281351
  • [Keywords] NOTNLM ; nodular basal cell carcinoma / skin phototype / sun exposure / superficial basal cell carcinoma
  •  go-up   go-down


Advertisement
4. Surrenti T, De Angelis L, Di Cesare A, Fargnoli MC, Peris K: Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. Eur J Dermatol; 2007 Sep-Oct;17(5):412-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
  • Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is a non-invasive therapy for superficial and nodular basal cell carcinoma (BCC).
  • We performed an open-label trial to evaluate efficacy, safety, tolerability and cosmetic outcome of MAL-PDT in selected patients with superficial and nodular BCCs.
  • Ninety-four superficial and 24 nodular BCCs in 69 patients were treated with 2 to 8 MAL-PDT sessions.
  • Complete clinical regression was detected in 84/94 (89.4%) superficial BCCs, and 12/23 (52.2%) nodular BCCs one month after 2 MAL-PDT sessions.
  • No further clinical improvement was observed in either superficial or nodular BCCs with treatment continuation up to a maximum of 8 MAL-PDT sessions.
  • Adverse effects were limited to mild local skin reactions, and cosmetic outcome was rated as excellent or good.
  • Based on the efficacy, tolerability, cosmetic outcome and recurrence rate, our results support the use of MAL-PDT for treatment of superficial BCC and for selected cases of nodular BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673385.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


5. Paoli J, Smedh M, Wennberg AM, Ericson MB: Multiphoton laser scanning microscopy on non-melanoma skin cancer: morphologic features for future non-invasive diagnostics. J Invest Dermatol; 2008 May;128(5):1248-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiphoton laser scanning microscopy on non-melanoma skin cancer: morphologic features for future non-invasive diagnostics.
  • This study describes the morphologic features of human non-melanoma skin cancer obtained using multiphoton laser scanning microscopy (MPLSM) on freshly excised specimens from 14 patients.
  • Traditional histopathological criteria such as bowenoid dysplasia, multinucleated cells, or hyperkeratosis in squamous cell carcinoma in situ (SCCIS) (five specimens), and peripheral palisading of tumor cells in superficial basal cell carcinoma (SBCC) (six specimens) were clearly discerned.
  • The morphologic features differed significantly between these lesions and perilesional skin.
  • However, characteristic tumor aggregates were found in only one of the three investigated nodular basal cell carcinomas (NBCCs) due to limited imaging depth.
  • In addition, speckled perinuclear fluorescence was observed in both lesions and normal perilesional skin.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Microscopy, Fluorescence, Multiphoton / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma in Situ / pathology. Dermis / pathology. Epidermis / pathology. Follow-Up Studies. Humans. Lasers

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989735.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Stashower ME: Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma. Cutis; 2006 Jul;78(1):66-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma.
  • A 73-year-old white man with nodular basal cell carcinoma (nBCC) of the toe and interdigital tinea pedis was treated with imiquimod cream 5% once daily for 4 weeks and twice daily for 10 weeks.
  • Results of a posttreatment potassium hydroxide (KOH) preparation and biopsy confirmed clearance of both tinea pedis and nBCC, respectively.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Tinea Pedis / drug therapy

  • MedlinePlus Health Information. consumer health - Athlete's Foot.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903324.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


7. Sapijaszko MJ: Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett; 2005 Jul-Aug;10(6):2-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
  • Skin cancer, the most common human cancer, is now a global epidemic.
  • The most prevalent form of nonmelanoma skin cancer is basal cell carcinoma (BCC), the incidence of which continues to increase prompting development of new treatment modalities designed to add or complement current therapies.
  • It enhances both the innate and acquired immune response, and has successfully treated both superficial and nodular basal cell carcinomas through the localized activation of elaborate immune response.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292452.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 14
  •  go-up   go-down


8. Neville JA, Williford PM, Jorizzo JL: Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol; 2007 Sep;6(9):910-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
  • BACKGROUND: Nodular basal cell carcinoma (nBCC) is the most common cutaneous malignancy and studies assessing the use of topical imiquimod 5% cream as a monotherapy in the treatment of nBCC have resulted in less than optimal clearance rates.
  • OBJECTIVE: This pilot study was designed to evaluate the efficacy of imiquimod 5% cream on nodular basal cell carcinoma lesions after initial treatment with curettage.
  • CONCLUSION: Imiquimod 5% cream appears to be an effective treatment method for nodular basal cell carcinoma if combined with curettage prior to application.
  • [MeSH-major] Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / drug therapy. Curettage / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941362.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


9. Rhodes LE, de Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, Wong GA, Richard MA, Anstey A, Wolf P: Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol; 2007 Sep;143(9):1131-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma.
  • OBJECTIVE: To compare 5-year lesion recurrence rates in primary nodular basal cell carcinoma treated with topical methyl aminolevulinate photodynamic therapy (PDT) or simple excision surgery.
  • CONCLUSIONS: Long-term follow-up indicates superior efficacy of surgery to methyl aminolevulinate PDT in nodular basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Photochemotherapy. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875873.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


10. Pye A, Campbell S, Curnow A: Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. J Cancer Res Clin Oncol; 2008 Aug;134(8):841-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
  • PURPOSE: Methyl-aminolevulinate (MAL) photodynamic therapy (PDT) is a cancer therapy that combines the selective accumulation of a photosensitizer in tumor tissue with visible light (and tissue oxygen) to produce reactive oxygen species.
  • This paper investigates this method of enhancement both in vitro and for the first time clinically for the treatment of nodular basal cell carcinoma (BCC).
  • METHODS: Enhancement of MAL-induced PpIX accumulation by the iron chelator CP94 was quantified fluorometrically in human cultured cells (including three dermatological cell types).
  • An open, dose-escalating, pilot study was then conducted in patients with nodular BCC, to determine the safety of this pharmacological modification.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Iron Chelating Agents / administration & dosage. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Pyridones / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Cell Line, Tumor. Humans. In Vitro Techniques. Middle Aged. Pilot Projects. Protoporphyrins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Nov;78(10):1278-82 [9823966.001]
  • [Cites] Chin Med J (Engl). 2004 Jun;117(6):922-6 [15198900.001]
  • [Cites] Photochem Photobiol. 2006 Sep-Oct;82(5):1334-41 [16771607.001]
  • [Cites] Br J Cancer. 1992 Dec;66(6):1070-6 [1457346.001]
  • [Cites] J Photochem Photobiol B. 1993 Mar;17(3):273-8 [8492244.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):409-12 [1558795.001]
  • [Cites] Cancer. 1997 Jun 15;79(12 ):2282-308 [9191516.001]
  • [Cites] J Photochem Photobiol B. 1997 Apr;38(2-3):114-22 [9203372.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):124-30 [12890205.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] J Photochem Photobiol B. 2006 Aug 1;84(2):161-6 [16624569.001]
  • [Cites] Cancer Res. 1978 Aug;38(8):2628-35 [667856.001]
  • [Cites] Photochem Photobiol. 1999 Jun;69(6):703-7 [10378010.001]
  • [Cites] Br J Cancer. 1995 Sep;72 (3):589-94 [7669566.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Photochem Photobiol. 1999 Jan;69(1):71-6 [10063802.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10 ):1525-32 [10408393.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Apr;22(2):105-10 [16606416.001]
  • [Cites] Br J Cancer. 1987 Nov;56(5):589-95 [3480752.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):688-97 [8795569.001]
  • [Cites] Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Jul;35(7):655-60 [12883637.001]
  • [Cites] Photochem Photobiol. 2007 May-Jun;83(3):766-73 [17576385.001]
  • [Cites] Br J Haematol. 1993 Oct;85(2):393-400 [8280612.001]
  • [Cites] Photochem Photobiol. 2002 Nov;76(5):518-25 [12462647.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):140-9 [9477772.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5824-32 [11479222.001]
  • [Cites] J Photochem Photobiol B. 1997 Nov;41(1-2):136-44 [9440321.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Cancer Lett. 1992 Aug 14;65(2):127-31 [1511416.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1045-51 [9028337.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):937-44 [8611429.001]
  • [Cites] Photochem Photobiol. 2003 Mar;77(3):304-8 [12685659.001]
  • (PMID = 18239941.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one; 585NM85KYM / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; C2K325S808 / protoporphyrin IX
  •  go-up   go-down


11. Campbell SM, Pye A, Horton S, Matthew J, Helliwell P, Curnow A: A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. J Environ Pathol Toxicol Oncol; 2007;26(4):295-303
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin.
  • This investigation considered a novel method of enhancing penetration of the topical photosensitizing agent methyl aminolevulinate (MAL) into nodular basal cell carcinomas (BCCs) using an oxygen pressure injection device.
  • Oxygen pressure injection (OPI) is a method to drive compounds into skin using pressured oxygen.
  • The study was an observer-blinded pilot of a single application of MAL to nBCCs, with or without the use of OPI.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell. Drug Delivery Systems / methods. Photosensitizing Agents. Skin Neoplasms
  • [MeSH-minor] Humans. Injections, Intralesional. Microscopy, Fluorescence. Ointments. Photochemotherapy. Pilot Projects. Protoporphyrins / metabolism. Skin Absorption

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197827.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


12. Mosterd K, Thissen MR, Nelemans P, Kelleners-Smeets NW, Janssen RL, Broekhof KG, Neumann HA, Steijlen PM, Kuijpers DI: Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol; 2008 Sep;159(4):864-70
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial.
  • BACKGROUND: Skin cancer incidence rates have been increasing for decades and this increase is expected to continue.
  • Surgical excision (SE) is the treatment of first choice for nodular basal cell carcinoma (nBCC).
  • Photodynamic therapy (PDT) has proven to be an effective treatment for superficial basal cell carcinoma.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Photosensitizing Agents / administration & dosage. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717680.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


13. Madan V, Loncaster JA, Allan D, Lear JT, Sheridan L, Leach C, Allan E: Nodular basal cell carcinoma in Gorlin's syndrome treated with systemic photodynamic therapy and interstitial optical fiber diffuser laser. J Am Acad Dermatol; 2006 Nov;55(5 Suppl):S86-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular basal cell carcinoma in Gorlin's syndrome treated with systemic photodynamic therapy and interstitial optical fiber diffuser laser.
  • Nodular basal cell carcinomas resistant to multiple forms of treatment in two patients with nevoid basal cell carcinoma syndrome (Gorlin's syndrome) were treated with systemic porfimer sodium-based photodynamic therapy.
  • [MeSH-major] Basal Cell Nevus Syndrome / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052541.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


14. Thompson MS, Andersson-Engels S, Svanberg S, Johansson T, Palsson S, Bendsoe N, Derjabo A, Kapostins J, Stenram U, Spigulis J, Svanberg K: Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery. J Environ Pathol Toxicol Oncol; 2006;25(1-2):411-24
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.
  • Twelve nodular basal cell carcinomas were treated employing delta-aminolevulinic acid and 635 nm laser irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Lasers. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566732.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


15. Kuzmina N, Talme T, Lapins J, Emtestam L: Non-invasive preoperative assessment of basal cell carcinoma of nodular and superficial types. Skin Res Technol; 2005 Aug;11(3):196-200
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive preoperative assessment of basal cell carcinoma of nodular and superficial types.
  • BACKGROUND/AIMS: Although various biophysical properties can be used to distinguish basal cell carcinoma (BCC) tissue from normal skin, none permits typing of the tumour.
  • In this study, we assessed nodular (NBCC) and superficial (SBCC) types of BCC using three different non-invasive instruments and placed special emphasis on their clinical value as diagnostic tools.
  • Measurements were also made in healthy skin on the contralateral side as reference.
  • CONCLUSIONS: As with LD and TEWL, definite differences in IMP were detected between healthy skin and BCC lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998331.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


16. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH: Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol; 2006 Jul-Aug;5(7):642-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) for basal cell carcinoma (BCC) is a treatment modality that is increasingly used in dermato-oncology.
  • OBJECTIVE: To evaluate the effect, degree of pain, and costs of ALA-PDT versus MAL-PDT in nodular BCC (nBCC).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865869.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


17. Brownell I: Nodular basal cell carcinoma: when in doubt, cut it out. J Drugs Dermatol; 2007 Dec;6(12):1245-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular basal cell carcinoma: when in doubt, cut it out.
  • Treating superficial basal cell carcinomas (BCCs) with photodynamic therapy or topical imiquimod can provide effective results in situations where an excisional approach is contraindicated or undesirable.
  • Numerous studies have sought to test these treatments for nodular BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189068.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


18. Spencer JM: Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg; 2006 Jan;32(1):63-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma.
  • BACKGROUND: Curettage and electrodesiccation (C&D) is a widely used method to treat nodular basal cell carcinoma (BCC).
  • OBJECTIVE: In a double-blind, vehicle-controlled study, the administration of imiquimod after C&D was investigated to determine if the combination regimen would reduce the frequency of residual tumor compared with C&D alone in patients with nodular BCC.
  • METHODS: Twenty patients received three cycles of C&D followed by imiquimod 5% or vehicle cream once daily for 1 month as adjunctive therapy.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Electrosurgery. Skin Neoplasms / therapy


19. Ly E, Durlach A, Antonicelli F, Bernard P, Manfait M, Piot O: Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy. Exp Dermatol; 2010 Jan;19(1):68-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing tumor and peritumoral tissues in superficial and nodular basal cell carcinoma using polarized Raman microspectroscopy.
  • Basal cell carcinoma (BCC) can sometimes lead, through a possible invasion of the dermis and the subcutaneous tissue, to serious local damage to the patient.
  • Several histological types of BCC are reported, among them, the superficial, nodular and infiltrative forms.
  • This study reports the use of polarized Raman microspectroscopy on the nodular and superficial types to discriminate between healthy epidermis and tumor, and between normal and peritumoral stroma.
  • Our findings also show that although superficial and nodular types of BCC were analysed, clear differences between the spectra of peritumoral and normal dermis could be detected.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Skin Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845756.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


20. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G: Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol; 2009 Aug;36(8):878-81
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.
  • An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder.
  • The adjacent unaffected skin showed a normal number of melanocytes and melanin pigment.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy. Vitiligo / chemically induced. Vitiligo / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Melanocytes / pathology. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586497.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


21. Smucler R, Vlk M: Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med; 2008 Feb;40(2):153-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma.
  • BACKGROUNDS AND OBJECTIVES: Photodynamic therapy (PDT), via topical aminolevulinic acid (ALA) is an effective treatment for basal cell carcinomas not exceeding a depth of 2 mm.
  • This limits the treatment of basal cell carcinoma (non-melanoma skin cancer) to superficial forms and nodular therapy (only in aesthetically desired locations).
  • STUDY DESIGN/MATERIALS AND METHODS: This study compared three methods for the treatment of recurring nodular basal cell carcinomas (r nBCC).
  • All three methods were used to treat to each patient, all subjects presenting with three or more basal cell carcinomas in order to eliminate differences in patient responsiveness to treatment.
  • Solitary Er:YAG laser ablation will remain however a fast, effective, and economical treatment alternative for simple manifestations of superficial basal cell carcinoma and has replaced PDT for uncomplicated cases at our facility.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Head and Neck Neoplasms / therapy. Laser Therapy / instrumentation. Lasers, Solid-State / therapeutic use. Photochemotherapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306163.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


22. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S: Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg; 2005 Mar;31(3):318-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
  • BACKGROUND: Imiquimod is an immune response modifier shown to be effective in basal cell carcinoma (BCC).
  • OBJECTIVE: To evaluate the efficacy, tolerability, and response durability of imiquimod 5% cream in selected patients with superficial and/or nodular BCCs.
  • METHODS: Seventy-five superficial and 19 nodular BCCs in 49 patients were treated with imiquimod once daily three times a week for up to 12 weeks.
  • Ten of 19 (52.6%) nodular BCCs cleared after 12 weeks, whereas 7 (36.8%) showed partial remission.
  • Adverse side effects were limited to local skin reactions.
  • No recurrence was detected in 68 of 70 (97.1%) superficial BCCs and in 10 successfully treated nodular BCCs after 12 to 34 months of follow-up (mean 23 months).
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841634.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


23. Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A: Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol; 2008 Aug;159(2):387-93
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) involves the activation of a photosensitizer by visible light to produce activated oxygen species within target cells, resulting in their destruction.
  • Evidence-based guidelines support the efficacy of PDT using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen disease and basal cell carcinoma (BCC).
  • Efficacy for nodular BCC appears inferior to that for superficial BCC unless prior debulking or repeat treatments are performed.
  • METHODS: A mixed topical formulation of ALA + increasing concentrations of CP94 was used to carry out PDT on previously biopsied nodular BCC with no prior lesion preparation using standard light delivery.
  • RESULTS: Enhanced PDT using 40% CP94 resulted in significantly greater clearance rates in nodular BCC than with ALA-PDT alone, in our protocol of single-treatment PDT with no lesion preparation.
  • CONCLUSIONS: The results of this study demonstrate the safe and effective use of an enhanced ALA-PDT protocol for nodular BCC using CP94, with no adverse reactions to this modification.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Iron Chelating Agents / therapeutic use. Photochemotherapy / methods. Pyridones / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2009 Jul;161(1):215-6 [19438852.001]
  • (PMID = 18544077.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


24. Blasi MA, Giammaria D, Balestrazzi E: Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol; 2005 Dec;140(6):1136-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma.
  • PURPOSE: To evaluate the efficacy and safety of topical imiquimod 5% cream for the treatment of eyelid basal cell carcinoma.
  • METHODS: Imiquimod 5% cream was applied topically once daily, 3 days a week for 8 to 12 weeks, in two patients affected by eyelid nodular basal cell carcinoma.
  • CONCLUSIONS: Topical imiquimod 5% cream seems to be a useful treatment for eyelid nodular basal cell carcinoma in selected cases, but further long-term studies are needed to assess the efficacy and safety of this approach.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Eyelid Neoplasms / drug therapy. Immunotherapy. Interferon Inducers / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376667.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


25. Wu JK, Oh C, Strutton G, Siller G: An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol; 2006 Feb;47(1):46-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
  • SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established.
  • This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs.
  • Curettage was used to de-bulk the lesion and confirm suitable histology.
  • Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma.
  • Curettage followed by imiquimod 5% cream is effective for the treatment of primary nodular basal cell carcinoma on the trunk and limbs, and most patients are pleased with the cosmetic outcome.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405483.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Emollients; 99011-02-6 / imiquimod
  •  go-up   go-down


26. van Oosten EJ, Kuijpers DI, Thissen MR: Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature. Photodiagnosis Photodyn Ther; 2006 Mar;3(1):61-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different pain sensations in photodynamic therapy of nodular basal cell carcinoma Results from a prospective trial and a review of the literature.
  • BACKGROUND: Pain is a major side effect of topical photodynamic therapy (PDT), a relatively new and non-invasive treatment for particular types of basal cell carcinoma (BCC).
  • METHODS: A total of 64 nodular BCCs in 55 patients, of which 48 BCCs underwent preceding debulking, were treated with 5-aminolevulinic acid (ALA-PDT).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049028.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, Lowe NJ, Jarratt MT, Murrell DF, Rich P, Pariser DM, Oseroff AR, Barnetson R, Anderson C, Kossard S, Gibson LE, Tope WD: Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol; 2009 Nov;48(11):1236-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
  • BACKGROUND: Data suggest that photodynamic therapy using topical methyl aminolevulinate (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell carcinoma (BCC).
  • In the studies described here, we investigated the histologic response, tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (<or= 5 mm in depth).
  • CONCLUSION: Although longer follow-up studies are required, these promising data indicate the potential of topical MAL PDT as a noninvasive treatment alternative for nodular BCC.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064185.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


28. Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, Radny P, Garbe C: A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol; 2007 Oct;57(4):616-21
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.
  • OBJECTIVE: The present study was planned to evaluate the efficacy and tolerability of topical treatment with imiquimod in nodular basal cell carcinoma (nBCC).
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610993.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Emollients; 99011-02-6 / imiquimod
  •  go-up   go-down


29. Rossman D, Arthurs B, Odashiro A, Saraiva V, Burnier M Jr: Basal cell carcinoma of the caruncle. Ophthal Plast Reconstr Surg; 2006 Jul-Aug;22(4):313-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the caruncle.
  • An 82-year-old white man presented with a 2- to 3-month history of a lesion in his left medial canthal region.
  • Surgical excision of the lesion was performed, and histopathology showed a nodular basal cell carcinoma of the caruncle.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Conjunctival Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855514.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Fien SM, Oseroff AR: Photodynamic therapy for non-melanoma skin cancer. J Natl Compr Canc Netw; 2007 May;5(5):531-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for non-melanoma skin cancer.
  • Photodynamic therapy (PDT) involves the administration of a photosensitizing drug and its subsequent activation by light at wavelengths matching the absorption spectrum of the photosensitizer.
  • Because the skin is readily accessible to light-based therapies, PDT with systemic and particularly with topical agents has become important in treating cutaneous disorders.
  • Topical PDT is indicated for treating actinic keratosis, superficial or thin non-melanoma skin cancer, including some cases of nodular basal cell carcinoma, and some cutaneous lymphomas.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Humans. Keratosis / drug therapy. Light. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509255.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA55791; United States / NCI NIH HHS / CA / P30CA16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 66
  •  go-up   go-down


31. Short MA, Lui H, McLean D, Zeng H, Alajlan A, Chen XK: Changes in nuclei and peritumoral collagen within nodular basal cell carcinomas via confocal micro-Raman spectroscopy. J Biomed Opt; 2006 May-Jun;11(3):34004
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in nuclei and peritumoral collagen within nodular basal cell carcinomas via confocal micro-Raman spectroscopy.
  • Confocal micro-Raman spectroscopy is used to probe the nuclei of normal human epidermal cells and epidermally derived cancer cells from nodular basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Collagen / analysis. Microscopy, Confocal / instrumentation. Spectrum Analysis, Raman / instrumentation
  • [MeSH-minor] Equipment Design. Equipment Failure Analysis. Humans. Reproducibility of Results. Sensitivity and Specificity. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822054.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


32. Rossi R, Bruscino N, Ricceri F, Grazzini M, Dindelli M, Lotti T: Photodynamic treatment for viral infections of the skin. G Ital Dermatol Venereol; 2009 Feb;144(1):79-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic treatment for viral infections of the skin.
  • Photodynamic therapy (ALA/MAL-PDT) is indicated for the treatment of actinic keratoses, for superficial, nodular basal cell carcinoma and for Bowen's disease; there is evidence that PDT can be active also against bacteria, viruses and fungi.
  • The new indications for PDT include many types of viral skin infections human papilloma virus (HPV)-related as verrucae of feet and hands, Condylomata acuminata, periungueal warts, epidermodysplasia verruciformis, but also viral skin lesions non HPV related as molluscum contagiosum and herpes simplex can be successfully treated.
  • [MeSH-major] Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Skin Diseases, Viral / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218913.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 26
  •  go-up   go-down


33. Sidoroff A: [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review]. Hautarzt; 2007 Jul;58(7):577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last years photodynamic therapy (PDT) has progressively established itself as a standard treatment for non-melanoma skin cancer.
  • For Bowen disease and superficial basal cell carcinoma, PDT can be regarded as the first-line non-invasive treatment.
  • In nodular basal cell carcinoma, effectiveness for lesions up to a thickness of 2 mm is well documented.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cosmet Laser Ther. 2003 Jun;5(2):107-10 [12850802.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S19-23 [12060513.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Acta Derm Venereol. 2005;85(6):483-90 [16396794.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Arch Dermatol Res. 1996 Sep;288(10):561-4 [8919036.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):767-72 [11069454.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2 Suppl):17-25 [16485877.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10):1313-20 [14568836.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 17522831.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


34. Choontanom R, Thanos S, Busse H, Stupp T: Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol; 2007 Aug;245(8):1217-20
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study.
  • BACKGROUND: The aim of this study was to determine the efficacy and safety of 5% topical imiquimod, and the long-term results following its use, in the treatment of nodular basal cell carcinoma (BCC) of the eyelid.
  • METHODS: Imiquimod cream (5%) was applied topically to five individuals affected by nodular BCC of the eyelid.
  • CONCLUSIONS: Topical imiquimod applied in the form of a 5% cream proved to be a safe, efficacious and sustainable treatment option for nodular BCC of the eyelid in our selected cases.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Eyelid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2003 Oct;139(10 ):1325-32 [14568837.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Cutan Med Surg. 2004;8 Suppl 3:3-12 [15647861.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Dermatol Surg. 2004 Mar;30(3):429-30 [15008876.001]
  • [Cites] Am J Ophthalmol. 2005 Dec;140(6):1136-9 [16376667.001]
  • (PMID = 17345092.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; P1QW714R7M / imiquimod
  •  go-up   go-down


35. Kemény L, Nagy N: [New perspective in immunotherapy: local imiquimod treatment]. Orv Hetil; 2010 May 9;151(19):774-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation of TLR7 results in the stimulation of the innate and acquired immune responses, in particular cell mediated immune pathways.
  • Topical imiquimod cream 5% (Aldara, MEDA Pharma) has been found to be effective for the treatment of actinic keratoses, superficial basal cell carcinoma and anogenital warts.
  • There are some data on its efficacy in nodular basal cell carcinoma and in some other skin cancers.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Adjuvants, Immunologic / therapeutic use. Aminoquinolines / pharmacology. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Condylomata Acuminata / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy. Toll-Like Receptors / immunology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427260.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / TLR7 protein, human; 0 / TLR8 protein, human; 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 8; 0 / Toll-Like Receptors; 99011-02-6 / imiquimod
  • [Number-of-references] 50
  •  go-up   go-down


36. Donnelly RF, Morrow DI, Fay F, Scott CJ, Abdelghany S, Singh RR, Garland MJ, Woolfson AD: Microneedle-mediated intradermal nanoparticle delivery: Potential for enhanced local administration of hydrophobic pre-formed photosensitisers. Photodiagnosis Photodyn Ther; 2010 Dec;7(4):222-31
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, owing to the poor penetration of ALA into skin, ALA-PDT is inappropriate for difficult-to-treat deep skin neoplasias, such as nodular basal cell carcinoma.
  • An alternative strategy to ALA-PDT is to use pre-formed photosensitisers, which can be activated at longer wavelengths, facilitating enhanced light penetration into skin.
  • This study aimed to deliver a model hydrophobic dye, Nile red, into the skin using novel microneedle (MN) technology.
  • Tissue penetration studies using excised porcine skin revealed that high tissue concentrations of Nile red were observed at 1.125mm (382.63ng cm(-3)) following MN delivery.
  • CONCLUSION: For the first time, polymeric microneedles (MN) have been employed to deliver a model lipophilic dye, Nile red, into excised porcine skin.
  • [MeSH-minor] Animals. Humans. Hydrophobic and Hydrophilic Interactions. In Vitro Techniques. Injections, Intradermal. Microscopy, Electron, Scanning. Needles. Particle Size. Skin Absorption. Swine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 21112544.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/E020534/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Oxazines; 0 / Photosensitizing Agents; 0 / polylactic acid-polyglycolic acid copolymer; 26009-03-0 / Polyglycolic Acid; 33X04XA5AT / Lactic Acid; P476F1L81G / nile red
  •  go-up   go-down


37. Shulstad RM: Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatol Nurs; 2009 Mar-Apr;21(2):86-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
  • An 85-year-old female presented to the office with a 3.5 x 2 cm basal cell carcinoma on her left neck.
  • Although not indicated for treating nodular basal cell carcinomas, imiquimod may be a viable option for large basal cell carcinomas when patients are unable or unwilling to have surgical interventions.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507375.001).
  • [ISSN] 1060-3441
  • [Journal-full-title] Dermatology nursing
  • [ISO-abbreviation] Dermatol Nurs
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


38. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM: Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol; 2008 Nov;159(5):1170-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo.
  • Nevertheless, the reported cure rates vary and the transdermal penetration of drugs has been discussed as a limiting factor, particularly for treatment of nodular basal cell carcinoma (BCC).
  • METHODS: Twenty patients with 27 histologically verified BCCs (13 superficial, 14 nodular) were included.
  • No difference was found when comparing superficial and nodular BCCs, and the effect of curettage was found to be negligible.
  • [MeSH-major] Aminolevulinic Acid / pharmacokinetics. Carcinoma, Basal Cell / metabolism. Photosensitizing Agents / pharmacokinetics. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717673.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


39. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA; 2005 Aug 10;294(6):681-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
  • CONTEXT: The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years.
  • OBJECTIVES: To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample.
  • PARTICIPANTS: Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003.
  • MAIN OUTCOME MEASURES: Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time.
  • RESULTS: During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients.
  • Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous cell carcinomas.
  • Overall, the age-adjusted incidence of basal cell carcinoma per 100,000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% CI, 17.8-23.9) for men.
  • The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P = .19).
  • Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype.
  • The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100 000 persons of 3.9 (95% CI, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P = .01) and men (P = .04).
  • CONCLUSIONS: This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota.
  • There was a disproportionate increase in basal cell carcinoma in young women.
  • This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418458.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):279; author reply 279-81 [16418459.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278-9; author reply 279-81 [16418456.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418457.001]
  • (PMID = 16091570.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Whitaker IS, Shokrollahi K, James W, Mishra A, Lohana P, Murison MC: Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas. Ann Plast Surg; 2007 Nov;59(5):484-8
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas.
  • BACKGROUND: Basal cell carcinomas (BCC) are often seen by plastic surgeons and dermatologists in the outpatient setting.
  • Treatment usually necessitates excision of these lesions with an appropriate margin guided by published recommendations, often resulting in less than ideal cosmetic outcomes, especially if local flaps or skin grafts are required for reconstruction.
  • These modalities when used alone have a number of limitations when compared with surgical excision, including a limited depth of penetration of PDT (2-mm absorption), which potentially limits the efficacy of treatment of nodular BCCs greater than this thickness or which are deeply invasive.
  • METHODS: Twelve patients with 13 biopsy-proven nodular BCCs on the head and neck were treated with combined therapy using an Ultra Pulse CO(2) and PDT using Methyl Aminolevulinate (METVIX) and the Aktilite 16 LED lamp.
  • CONCLUSION: In this study, CO(2) laser and PDT appear to play a synergistic role in the treatment of nodular basal cell carcinomas.
  • [MeSH-major] Carbon Dioxide / chemistry. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / therapy. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / therapy. Lasers. Photochemotherapy / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992139.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


41. Shah SM, Konnikov N, Duncan LM, Tannous ZS: The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med; 2009 Aug;41(6):417-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas.
  • BACKGROUND AND OBJECTIVE: Basal cell carcinomas (BCCs) have supporting vasculature that could serve as a target for 595 nm pulsed dye laser (PDL).
  • The objective of this study was to determine the effect of repeated PDL treatments on BCCs of superficial and nodular subtypes and of varying diameters.
  • The tumor and 4 mm of peripheral skin were treated using a set of previously optimized laser parameters: one pass, 15 J/cm2 energy, 3 ms pulse length, no cooling, and 7 mm spot size with 10% overlap.
  • Tumor histologic types among the complete responders included superficial, nodular, micronodular, and keratinizing.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiotherapy. Lasers, Dye / therapeutic use. Low-Level Light Therapy. Skin Neoplasms / pathology. Skin Neoplasms / radiotherapy


42. Desai TD, Desai AD, Horowitz DC, Kartono F, Wahl T: The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas. Dermatol Surg; 2007 Oct;33(10):1220-7; discussion 1226-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas.
  • BACKGROUND: Frequencies of 20 MHz may be appropriate to visualize basal cell carcinomas (BCCs) including their tumor thickness and margins.
  • MATERIALS AND METHODS: Fifty superficial and nodular BCCs of various locations were scanned using a 20-MHz ultrasound device.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903155.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Muller FM, Dawe RS, Moseley H, Fleming CJ: Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg; 2009 Sep;35(9):1349-54
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome.
  • BACKGROUND: Mohs micrographic surgery (MMS) is recognized globally as the criterion standard for high-risk basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500127.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00571363
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Vun Y, Siller G: Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol; 2006 Aug;47(3):169-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
  • There has been considerable research into the safety and efficacy of topical 5% imiquimod cream for the treatment of skin cancers in recent years, in particular superficial and nodular basal cell carcinomas.
  • This retrospective study aims to determine the efficacy of 5% imiquimod cream in the treatment of facial basal cell carcinomas over 3 years.
  • Target tumours included superficial and nodular basal cell carcinomas, giving a total lesion number of 19.
  • We found that 5% imiquimod cream is an effective treatment option for superficial and nodular basal cell carcinomas, giving a clearance rate of 89.5% at an average of 39 months of follow up.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Facial Neoplasms / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866996.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


45. Rose RF, Merchant W, Stables GI, Lyon CL, Platt A: Basal cell carcinoma with a sarcomatous component (carcinosarcoma): a series of 5 cases and a review of the literature. J Am Acad Dermatol; 2008 Oct;59(4):627-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with a sarcomatous component (carcinosarcoma): a series of 5 cases and a review of the literature.
  • Each tumor had an epithelial component resembling a typical nodular basal cell carcinoma.
  • [MeSH-major] Carcinosarcoma / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793937.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


46. Hunzeker CM, Soldano AC, Prystowsky S: Epidermodysplasia verruciformis. Dermatol Online J; 2008;14(5):2
Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A biopsy specimen of the ulcerated nodule showed a nodular basal-cell carcinoma.
  • Two additional biopsy specimens from her forehead showed one invasive and one in-situ squamous-cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627738.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Satter EK, Derienzo DP: Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp. J Cutan Pathol; 2008 Jul;35(7):685-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp.
  • Merkel cell carcinoma (MCC) is a rare aggressive neoplasm that typically presents as a solitary nodule or plaque on sun-exposed skin of the elderly.
  • We report a case of a 59-year-old white male who presented with abrupt onset of multiple small bluish papules on his frontal scalp.
  • On low power, the tumor had the overall histological silhouette of a nodular basal cell carcinoma.
  • However, because of the lack of an epithelial connection and the cell's cytomorphological features, a MCC was considered and was subsequently confirmed using immunohistochemical stains.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331571.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Del Rosso JQ: The treatment of viral infections and nonmelanoma skin cancers. Cutis; 2007 Apr;79(4 Suppl):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of viral infections and nonmelanoma skin cancers.
  • Immunomodulatory therapy, which functions to upregulate immune response, may be directed against a variety of disease states, including viral infections and skin malignancies.
  • Topical imiquimod has been studied for a variety of different disorders including human papillomavirus infection, molluscum contagiosum, actinic keratosis (AK), squamous cell carcinoma (SCC) in situ, superficial basal cell carcinoma (sBCC), nodular basal cell carcinoma (nBCC), and lentigo maligna.
  • This article focuses on therapies designed to augment immune response to treat viral infections and nonmelanoma skin cancers and reviews clinical applications, efficacy, recommended treatment regimens, monitoring of response, and avoidance of pitfalls associated with the use of topical imiquimod.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Interferons / therapeutic use. Skin Diseases, Viral / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508493.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  • [Number-of-references] 53
  •  go-up   go-down


49. Thompson MS, Johansson A, Johansson T, Andersson-Engels S, Svanberg S, Bendsoe N, Svanberg K: Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. Appl Opt; 2005 Jul 1;44(19):4023-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from the first clinical treatments on nodular basal cell carcinomas indicate a major treatment-induced light absorption increase, rapid sensitizer photobleaching, and a relatively constant global tissue oxygen saturation level during the treatment.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Carcinoma, Basal Cell / drug therapy. Fiber Optic Technology / instrumentation. Photochemotherapy / instrumentation. Skin Neoplasms / drug therapy. Spectrometry, Fluorescence / instrumentation. Therapy, Computer-Assisted / instrumentation. User-Computer Interface

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004049.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


50. Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA, International Society for Photodynamic Therapy in Dermatology: Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol; 2007 Jan;56(1):125-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.
  • Topical photodynamic therapy (PDT) is used to treat nonmelanoma skin cancers, such as actinic keratoses, Bowen's disease, and basal cell carcinoma (superficial and nodular).
  • This article presents up-to-date, practical, evidence-based recommendations on the use of topical PDT using 5-aminolevulinic acid or methyl aminolevulinate for the treatment (and prevention) of nonmelanoma skin cancers.
  • Topical PDT is highly effective in the treatment of actinic keratoses, Bowen's disease, superficial and thin nodular basal cell carcinomas, with cosmesis typically superior to that achieved with existing standard therapies.
  • PDT may also be a means of preventing certain nonmelanoma skin cancers in immunosuppressed patients.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Australia / epidemiology. Basal Cell Nevus Syndrome / drug therapy. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Double-Blind Method. Humans. Immunocompromised Host. Incidence. Keratosis / drug therapy. Multicenter Studies as Topic. Patient Satisfaction. Photosensitivity Disorders / drug therapy. Randomized Controlled Trials as Topic. Skin Diseases / drug therapy. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190630.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 91
  •  go-up   go-down


51. Warshauer E, Warshauer BL: Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol; 2008 May;7(5):447-51
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
  • The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at a community-based dermatology practice were retrospectively reviewed.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505136.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


52. Salomatina E, Jiang B, Novak J, Yaroslavsky AN: Optical properties of normal and cancerous human skin in the visible and near-infrared spectral range. J Biomed Opt; 2006 Nov-Dec;11(6):064026
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical properties of normal and cancerous human skin in the visible and near-infrared spectral range.
  • Differences in absorption and/or scattering of cancerous and normal skin have the potential to provide a basis for noninvasive cancer detection.
  • In this study, we have determined and compared the in vitro optical properties of human epidermis, dermis, and subcutaneous fat with those of nonmelanoma skin cancers in the spectral range from 370 to 1600 nm.
  • Fresh specimens of normal and cancerous human skin were obtained from surgeries.
  • In this spectral region, the scattering of cancerous lesions is consistently lower than that of normal tissues, whereas absorption does not differ significantly, with the exception of nodular basal cell carcinomas (BCC).
  • Nodular BCCs exhibit significantly lower absorption as compared to normal skin.
  • Therefore, the spectral range between 1050 and 1400 nm appears to be optimal for nonmelanoma skin cancer detection.
  • [MeSH-major] Skin / pathology. Skin / physiopathology. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology. Spectrophotometry, Infrared / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212549.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Huerva V, Sanchez MC, Egido RM, Matías-Guiu X: Pleomorphic adenoma with extensive myoepithelial component (myoepithelioma) of the lower eyelid. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):223-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 58-year-old woman presented with a nodular lesion on the medial part of her left lower eyelid.
  • On presentation to us, the lesion showed a clinical appearance that was very similar to a nodular basal cell carcinoma.
  • The authors conclude that myoepithelioma should be considered in the differential diagnosis of nodular recurrent masses in the eyelids of adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520841.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Fernández-Guarino M, García-Morales I, Harto A, Montull C, Pérez-García B, Jaén P: [Photodynamic therapy: new indications]. Actas Dermosifiliogr; 2007 Jul-Aug;98(6):377-95
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) is approved for the treatment of actinic keratoses, superficial and nodular basal cell carcinomas, and recently, Bowen's disease.
  • The experience in psoriasis, acne, common warts and cutaneous T cell lymphoma starts to be broad and interesting, which permits to define its use in these entities.
  • In this paper we review the treatment of Bowen's disease and other indications different from non melanoma skin cancer with PDT, providing our experience.
  • [MeSH-major] Photochemotherapy / trends. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Bowen's Disease / drug therapy. Dermatitis / drug therapy. Female. Humans. Male. Pain / etiology. Patient Dropouts. Photosensitizing Agents / therapeutic use. Psoriasis / drug therapy. Skin Diseases, Infectious / drug therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17663928.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 123
  •  go-up   go-down


55. Morrow DI, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A, Iani V, Moan J, Donnelly RF: Hexyl aminolaevulinate is a more effective topical photosensitiser precursor than methyl aminolaevulinate and 5-aminolaevulinic acids when applied in equimolar doses. J Pharm Sci; 2010 Aug;99(8):3486-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aminolaevulinic acid (ALA) is known to poorly penetrate into thick lesions, such as nodular basal cell carcinomas.
  • Short chain ALA esters, possessing increased lipophilicity relative to their hydrophilic parent, have previously been shown to be highly efficient at inducing protoporphyrin IX (PpIX) production in cell culture, at equimolar concentrations.
  • In contrast, in vitro skin permeation and in vivo animal studies, which up to now have compared prodrugs on a % w/w basis, have failed to demonstrate such benefits.
  • In vitro penetration studies into excised porcine skin revealed that increased levels of h-ALA, compared to ALA and m-ALA were found in the upper skin layers, at all drug loadings studied.
  • Topical application of the formulations to nude murine skin in vivo, revealed that creams containing h-ALA induced significantly higher levels of peak PpIX fluorescence (F(max) = 289.0) at low concentrations compared to m-ALA (F(max) = 159.2) and ALA (F(max) = 191.9).
  • Importantly, this study indicates that when compared on an equimolar basis, h-ALA has improved skin penetration, leading to enhanced PpIX production compared to the parent drug and m-ALA.
  • [MeSH-minor] Administration, Topical. Animals. Animals, Newborn. Chemistry, Pharmaceutical. Drug Delivery Systems. In Vitro Techniques. Isotope Labeling. Mice. Mice, Inbred BALB C. Ointments. Skin / chemistry. Skin / drug effects. Skin Absorption. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20222026.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ointments; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


56. Kazakov DV, Vanecek T, Nemcova J, Kacerovska D, Spagnolo DV, Mukensnabl P, Michal M: Spectrum of tumors with follicular differentiation in a patient with the clinical phenotype of multiple familial trichoepitheliomas: a clinicopathological and molecular biological study, including analysis of the CYLD and PTCH genes. Am J Dermatopathol; 2009 Dec;31(8):819-27
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a patient with multiple trichoepitheliomas whose biopsy material also demonstrated a range of other neoplasms with follicular differentiation, including small nodular trichoblastoma, small nodular basal cell carcinoma (BCC), and areas resembling infundibulocystic BCC/basaloid follicular hamartoma.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / pathology. Neoplasms, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Receptors, Cell Surface / genetics. Skin Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Differentiation. Child. Female. Humans. Male. Pedigree. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730223.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Receptors, Cell Surface; 0 / Tumor Suppressor Proteins; 0 / patched receptors
  •  go-up   go-down


57. Yébenes M, Toll A, Vélez M, Barranco C, Alonso-López NA, Gonzalez-Sarmiento R, Bellosillo B, Pujol RM: Linear unilateral hamartomatous basal cell naevus with glandular and follicular differentiation. Clin Exp Dermatol; 2008 Jul;33(4):429-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear unilateral hamartomatous basal cell naevus with glandular and follicular differentiation.
  • Mosaicisms are characterized by genetic or functional differences between > or = 2 cell lines in one person, derived from a single zygote.
  • Of the various clinical patterns of cutaneous mosaicism, linear lesions following Blaschko's lines are probably the most commonly encountered, Several cases of multiple basal cell carcinomas or basaloid hamartomatous lesions distributed in a segmentary distribution and following Blaschko's lines have been described.
  • The various terms of 'linear unilateral basal cell naevus with comedones', 'linear unilateral basaloid follicular hamartoma', 'linear unilateral basal cell naevus', and 'basal-cell and linear unilateral adnexal hamartoma' have been used to define this apparently heterogeneous group of disorders.
  • We report a 66-year-old woman with a linear unilateral lesion that appeared during puberty and that histologically showed an adnexal hamartomatous lesion with multiple superficial and nodular basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hair Follicle / pathology. Hamartoma / pathology. Mosaicism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312461.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Jacyk WK, Rütten A, Requena L: Fibrous papule of the face with granular cells. Dermatology; 2008;216(1):56-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It presents usually as a single small, firm, skin-coloured papule and is often misdiagnosed as melanocytic naevus, wart or small nodular basal cell carcinoma.
  • Uncommon histopathologic variants of fibrous papule of the face include hypercellular, clear-cell, pleomorphic, pigmented, inflammatory and granular-cell types.
  • Probably the occurrence of the granular-cell fibrous papule of the face was coincidental.
  • [MeSH-major] Angiofibroma / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • [CommentIn] Dermatology. 2008;217(1):56-7; author reply 57 [18382105.001]
  • (PMID = 18032900.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Marty CL, Randle HW, Walsh JS: Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatol Surg; 2005 Jul;31(7 Pt 1):780-2; discussion 782-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy.
  • There was no evidence of residual basal cell carcinoma.
  • We report its successful use in the treatment of a nodular basal cell carcinoma.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Skin Diseases / etiology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029707.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Retinoids; 99011-02-6 / imiquimod
  •  go-up   go-down


60. Garcia-Martin E, Idoipe M, Gil LM, Pueyo V, Alfaro J, Pablo LE, Zubiri ML, Fernandez J: Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocul Pharmacol Ther; 2010 Aug;26(4):373-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
  • PURPOSE: To assess the efficacy and safety of nonsurgical treatment with imiquimod (IMQ) 5% cream in patients with periocular nodular basal cell carcinoma (BCC).
  • METHODS: Fifteen patients with clinical and histopathological diagnosis of nodular BCC on the eyelid were treated with IMQ 5% cream once daily, 5 days/week for 6 weeks.
  • [MeSH-major] Aminoquinolines / administration & dosage. Aminoquinolines / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Eyelid Neoplasms / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698800.001).
  • [ISSN] 1557-7732
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / carbomer; 99011-02-6 / imiquimod
  •  go-up   go-down


61. Wadhera A, Fazio M, Bricca G, Stanton O: Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J; 2006;12(5):7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data?
  • A 55-year-old man presented to Skin Cancer Surgery Center of Sacramento in 1995 for Mohs micrographic surgery of a 1.5-cm nodular basal cell carcinoma located on the right superior antihelix and scaphoid fossa.
  • A recurrent basal cell carcinoma developed at the same site 5 years later and was treated also by Mohs micrographic surgery.
  • One year later (approximately 6 years after the diagnosis of the initial basal cell carcinoma), a right parotid mass was noted on routine physical exam.
  • CT scan and fine needle aspiration of the mass revealed metastatic basal cell carcinoma.
  • Basal cell carcinoma is the most common malignancy in the world.
  • We report a case of basal cell carcinoma metastatic to the parotid gland and critically review the incidence data reported in the literature.
  • We recommended the collection of more current and accurate incidence data for basal cell carcinoma and metastatic basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Ear Neoplasms / pathology. Parotid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962022.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


62. Gilmore BF, McCarron PA, Morrow DI, Murphy DJ, Woolfson AD, Donnelly RF: In vitro phototoxicity of 5-aminolevulinic acid and its methyl ester and the influence of barrier properties on their release from a bioadhesive patch. Eur J Pharm Biopharm; 2006 Jul;63(3):295-309
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to its hydrophilicity, ALA penetrates deep lesions, such as nodular basal cell carcinomas (BCCs) poorly.
  • In this study, the in vitro release of ALA and M-ALA from proprietary creams and novel patch-based systems across normal stratum corneum and a model membrane designed to mimic the abnormal stratum corneum overlying neoplastic skin lesions were investigated.
  • Receiver compartment drug concentrations were compared with the concentrations of each drug producing high levels of PpIX production and subsequent light-induced kill in a model neoplastic cell line (LOX).
  • However, drug concentrations achieved in receiver compartments were comparable to those required to induce high levels of cell death upon irradiation in cell lines reported in the literature.
  • [MeSH-minor] Cell Line, Tumor. Chemistry, Pharmaceutical. Chromatography, High Pressure Liquid. Humans. Membranes, Artificial. Ointments. Protoporphyrins / biosynthesis. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682177.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membranes, Artificial; 0 / Ointments; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


63. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • The sebaceous tumors that were examined in this study included sebaceous adenomas, sebaceous epitheliomas (sebaceomas) and sebaceous carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • RESULTS: CK 19 was focally positive in 1/5 (20%) sebaceous adenomas, 8/16 (50%) of sebaceous epitheliomas and 1/6 (17%) of sebaceous carcinomas.
  • Strongly positive expression of CK 19 was not seen in any of the sebaceous adenoma, sebaceous epithelioma or sebaceous carcinoma specimens.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


64. Mougel F, Debarbieux S, Ronger-Savlé S, Dalle S, Thomas L: Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy. Dermatology; 2009;219(2):138-42
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylaminolaevulinate photodynamic therapy in patients with multiple basal cell carcinomas in the setting of Gorlin-Goltz syndrome or after radiotherapy.
  • BACKGROUND: The naevoid basal cell carcinoma syndrome (NBCCS) is a therapeutic challenge due to the multiplicity of cutaneous tumours.
  • Photodynamic therapy (PDT) is increasingly used as an alternative treatment for superficial and in some countries nodular basal cell carcinomas (BCC).
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Basal Cell Nevus Syndrome / drug therapy. Basal Cell Nevus Syndrome / radiotherapy. Neoplasm Recurrence, Local / pathology. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19590166.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


65. Donnelly RF, Morrow DI, McCarron PA, Garland MJ, Woolfson AD: Influence of solution viscosity and injection protocol on distribution patterns of jet injectors: application to photodynamic tumour targeting. J Photochem Photobiol B; 2007 Dec 14;89(2-3):98-109
Hazardous Substances Data Bank. POLYVINYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy of deep or nodular skin tumours is currently limited by the poor tissue penetration of the porphyrin precursor 5-aminolevulinic acid (ALA) and preformed photosensitisers.
  • In this study, we investigated the potential of jet injection to deliver both ALA and a preformed photosensitiser (meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate, TMP) into a defined volume of skin.
  • Studies with neonate porcine skin revealed that an injection protocol comprising an 8.98 mPas solution, an arbitrary injection setting of 8 and a standoff distance of zero was capable of delivering photosensitisers to a volume of tissue (L(t) of 2.91 mm, L(m) of 2.14 mm, L(w) of 5.10 mm) comparable to that occupied by a typical nodular basal cell carcinoma.
  • Consequently, jet injection may be suitable for selective targeting of ALA or preformed photosensitisers to skin tumours.
  • [MeSH-major] Injections, Jet / methods. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962035.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / VS/06/QUEENB/A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hydrogels; 0 / Porphyrins; 38673-65-3 / tetra(4-N-methylpyridyl)porphine; 88755TAZ87 / Aminolevulinic Acid; 9002-89-5 / Polyvinyl Alcohol
  •  go-up   go-down


66. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M: Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol; 2010 Aug;37(8):886-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors.
  • The available histopathological material included 24 trichoepitheliomas, 2 large nodular basal cell carcinomas (BCCs), 2 spiradenomas, 1 spiradenocylindroma and 1 trichoblastoma composed of large and small nodules with prominent clear cell differentiation.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Skin Appendage / genetics. Facial Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132422.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


67. Al-Arashi MY, Salomatina E, Yaroslavsky AN: Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers. Lasers Surg Med; 2007 Oct;39(9):696-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers.
  • BACKGROUND AND SIGNIFICANCE: The standard diagnostic procedure for skin cancers is invasive biopsy followed by histopathological evaluation.
  • In this study, the suitability of dye-enhanced multimodal confocal microscopy for the detection of nonmelanoma skin cancers was evaluated.
  • Reflectance, fluorescence, and fluorescence polarization images of skin specimens stained with MB and TB were excited by 656 nm and 633 nm light, respectively.
  • In total we imaged, analyzed, and compared to histology at least 10 samples of each tumor-type including nodular basal cell carcinoma (BCC), infiltrative basal cell carcinoma, and squamous cell carcinoma (SCC).
  • RESULTS AND CONCLUSION: The morphological features and appearance of skin structures in the fluorescence images correlate well with corresponding histology for all investigated tumor-types.
  • Our results indicate the feasibility of using multimodal confocal microscopy as real-time tool for detecting skin pathology.
  • [MeSH-major] Microscopy, Confocal. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Coloring Agents. Diagnosis, Differential. Equipment Design. Humans. In Vitro Techniques. Methylene Blue. Staining and Labeling. Tolonium Chloride

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17960751.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
  •  go-up   go-down


68. Donnelly RF, Juzenas P, McCarron PA, Ma LW, Woolfson AD, Moan J: Influence of formulation factors on methyl-ALA-induced protoporphyrin IX accumulation in vivo. Photodiagnosis Photodyn Ther; 2006 Sep;3(3):190-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) is a medical treatment by which a combination of a photosensitising drug and visible light cause the destruction of selected cells.
  • Thick lesions, such as nodular basal cell carcinomas (BCCs), or lesions with overlying keratinous debris, are reported as being difficult to eradicate using 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT).
  • Pressure sensitive adhesive (PSA) and bioadhesive patches containing defined M-ALA loadings and a standard cream containing equivalent amounts of drug were applied to the skin of mice for defined periods of time and the fluorescence of the protoporphyrin IX (PpIX) induced measured over 24h.
  • PSA patches would be most suitable for application to areas of dry skin, while bioadhesive patches would be suitable for moist areas, such as the mouth or lower female reproductive tract and have been shown here to induce significant PpIX production at the site of application after 4h applications of patches containing high drug loadings.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25049154.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Morrow DI, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A, Iani V, Moan J, Donnelly RF: Novel patch-based systems for the localised delivery of ALA-esters. J Photochem Photobiol B; 2010 Oct 5;101(1):59-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, ALA does not possess favourable physicochemical properties for skin penetration.
  • Consequently, the clearance rates for difficult to treat lesions, such as nodular basal cell carcinomas are relatively low.
  • In vitro penetration studies into excised porcine skin revealed that ALA patches containing relatively high loadings (226.7 micromol cm(-2)) were associated with significantly greater tissue concentrations (70.7 micromol cm(-3)) than patches containing m-ALA (16.3 micromol cm(-3)) or h-ALA (17.4 micromol cm(-3)).
  • Bioadhesive preparations containing ALA are ideal for delivery to moist environments; whereas h-ALA-loaded PSA systems may facilitate enhanced delivery to dry areas of skin.
  • [MeSH-minor] Administration, Topical. Animals. Carcinoma, Basal Cell / drug therapy. Disease Models, Animal. Esters. Mice. Microscopy, Fluorescence. Photochemotherapy. Protoporphyrins / metabolism. Skin Neoplasms / drug therapy. Swine. Tissue Adhesives / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20634088.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Esters; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / Tissue Adhesives; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


70. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Morrow DI, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A, Iani V, Moan J, Donnelly RF: Influence of penetration enhancers on topical delivery of 5-aminolevulinic acid from bioadhesive patches. J Pharm Pharmacol; 2010 Jun;62(6):685-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poor penetration of ALA has been implicated as the primary factor for low response rates achieved with topical ALA-based photodynamic therapy of thicker neoplastic lesions, such as nodular basal cell carcinomas.
  • KEY FINDINGS: In-vitro depth penetration studies into excised porcine skin showed that high concentrations of ALA (>9 micromol/cm(3)) could be delivered to a depth of 1.875 mm.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Excipients / chemistry. Photosensitizing Agents / administration & dosage. Skin Absorption

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636855.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Excipients; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


72. Reddy KK, Hanke CW, Tierney EP: Rapid wound re-epithelialization and basal cell carcinoma clearance after Mohs micrographic surgery with postoperative photodynamic therapy. J Drugs Dermatol; 2010 Feb;9(2):143-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid wound re-epithelialization and basal cell carcinoma clearance after Mohs micrographic surgery with postoperative photodynamic therapy.
  • BACKGROUND: Methyl aminolevulinic acid photodynamic therapy (MAL-PDT) has antitumor activity and may promote wound healing Superficial and nodular basal cell carcinomas (BCCs) have been successfully treated with MAL-PDT in prior reports.
  • OBJECTIVES: To describe a novel case of a large multifocal BCC treated with postoperative PDT that showed results of tumor clearance and rapid re-epithelialization and to review the relevant literature.
  • Review of the literature relevant to use of MAL-PDT in treatment of basal cell carcinoma and literature describing effects of PDT on wound healing was performed.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / therapy. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214177.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Silva JN, Galmiche A, Tomé JP, Boullier A, Neves MG, Silva EM, Capiod JC, Cavaleiro JA, Santus R, Mazière JC, Filipe P, Morlière P: Chain-dependent photocytotoxicity of tricationic porphyrin conjugates and related mechanisms of cell death in proliferating human skin keratinocytes. Biochem Pharmacol; 2010 Nov 1;80(9):1373-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chain-dependent photocytotoxicity of tricationic porphyrin conjugates and related mechanisms of cell death in proliferating human skin keratinocytes.
  • Photodynamic therapy (PDT) is a poor treatment option for nodular basal cell carcinomas and squamous cell carcinomas.
  • The photocytotoxicity of conjugates (P-R) of a water-soluble tri-cationic porphyrin (P-H) having similar efficiency of production of singlet oxygen, the PDT cytotoxin, has been assessed in vitro.
  • Links between uptake, intracellular localization, photooxidative stress, photocytotoxicity and ability to induce programmed cell death are established.
  • The photocytotoxic potential of P-Me, P-OGal and P-DDC equals that of endogenous protoporphyrin IX induced by δ-aminolevulinic acid or its esters, the pro-drugs currently employed for PDT of skin lesions.
  • Absence of annexin V binding, caspase activation or chromatin condensation suggests that cell photosensitization by P-R does not induce apoptosis.
  • Given their potentially easy formulation, water-soluble P-R are promising powerful photosensitizers for PDT of skin lesions.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20691164.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Porphyrins; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  •  go-up   go-down


74. Devirgiliis V, Panasiti V, Curzio M, Gobbi S, Rossi M, Roberti V, Calvieri S: Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatol Online J; 2008;14(2):25
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700128.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


75. Mangano A, Albertin A, La Colla L: Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: when statistics make a difference. Br J Dermatol; 2009 Jul;161(1):215-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: when statistics make a difference.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Iron Chelating Agents / therapeutic use. Photochemotherapy / methods. Pyridones / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2010 Jan;162(1):224-5 [19903172.001]
  • [CommentOn] Br J Dermatol. 2008 Aug;159(2):387-93 [18544077.001]
  • (PMID = 19438852.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one
  •  go-up   go-down


76. Curnow A, Campbell SM: Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification. Br J Dermatol; 2010 Jan;162(1):224-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Iron Chelating Agents / administration & dosage. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Pyridones / administration & dosage. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2009 Jul;161(1):215-6 [19438852.001]
  • (PMID = 19903172.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one
  •  go-up   go-down


77. Lin MH, Lee JY, Ou CY, Wong TW: Sequential systemic retinoid and photodynamic therapy for multiple keratotic pigmented nodular basal cell carcinomas on the scalp. J Dermatol; 2009 Sep;36(9):518-21
Hazardous Substances Data Bank. ETRETINATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential systemic retinoid and photodynamic therapy for multiple keratotic pigmented nodular basal cell carcinomas on the scalp.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Etretinate / therapeutic use. Neoplasms, Multiple Primary / drug therapy. Photochemotherapy. Scalp. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2003 Jul;149(1):205-6 [12890225.001]
  • (PMID = 19712282.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratolytic Agents; 65M2UDR9AG / Etretinate
  •  go-up   go-down


78. Taibjee SM, Gee BC, Sanders DS, Smith A, Carr RA: Lentigo maligna involving the tumour nests and stroma of a nodular basal cell carcinoma. Br J Dermatol; 2007 Jul;157(1):184-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lentigo maligna involving the tumour nests and stroma of a nodular basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Hutchinson's Melanotic Freckle / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Radiation-Induced / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578442.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


79. Berroeta L, Clark C, Dawe RS, Ibbotson SH, Fleming CJ: A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol; 2007 Aug;157(2):401-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Curettage. Photochemotherapy / methods. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573890.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


80. Moehrle M, Breuninger H, Schippert W, Häfner HM: Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study. Dermatol Surg; 2010 Mar;36(3):428-30
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Mohs Surgery. Neoadjuvant Therapy. Nose Neoplasms / drug therapy. Nose Neoplasms / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dermatol Surg. 2009 Jan;35(1):24-9 [19018814.001]
  • (PMID = 20402949.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement